We demonstrate that activation of innate immune responses to arbovirus at the mosquito bite is a limiting factor for preventing efficient systemic dissemination of virus and that therapeutic targeting of skin-resident macrophages can have defining inhibitory effects on the later systemic course. 
Introduction
Emerging and re-emerging arboviruses pose an increasing threat to human health. There has been a substantial increase in both the incidence and geographical range of medicallyimportant arboviruses spread by mosquitoes, which infect hundreds of millions of people each 50 year and include the Zika (ZIKV), dengue (DENV) and chikungunya (CHIKV) viruses.
Arboviruses are a large, genetically-diverse group of viruses that cause a wide spectrum of diseases in humans (1) (2) (3) (4) (5) . Despite their genetic diversity, it is nonetheless difficult to clinically differentiate between these infections in the early stages of disease, as they are either asymptomatic or present as a non-specific febrile viral illness. In many geographic areas this 55 is compounded by the widespread co-circulation of distinct species of arboviruses in the same geographic area (6) . Together, these factors complicate the use of putative virus-specific antivirals, which for acute infections are most often only efficacious when given during early stages (7) . This, when combined with our inability to accurately predict the timing and location of future epidemics (8) , makes stockpiling future virus-specific drugs and vaccines difficult.
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Currently, there are few vaccines and no antivirals available for arbovirus infections. We suggest that due to the diversity of arbovirus genetics, their common clinical features and their unpredictable epidemiology, the development of a pan-viral medicine that is efficacious for multiple arbovirus infections would be highly advantageous.
Infected mosquitoes deposit virus into the skin dermis as they probe for a bloodmeal,
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triggering activation of distinct inflammatory pathways in response to mosquito biting and to virus sensing (9) (10) (11) . We and others have demonstrated that host responses in the skin to mosquito biting, or mosquito saliva, has a defining influence on the systemic course of infection for a wide-variety of genetically-distinct arboviruses including flaviviruses, alphaviruses and bunyaviruses (10, 12, 13) . As such, this is a key stage of infection during which 70 virus replicates rapidly before disseminating to the blood and remote tissues. However, some of the original virus inoculum also disseminates directly to the blood and the draining lymph node (dLN) where replication is also established prior to systemic dissemination (9, 14) . Thus, it is not clear what role skin-specific innate immune responses, activated by virus sensing at the mosquito bite, has on modulating the subsequent systemic course. In this study, we 75 wanted to define the relevance of skin virus-sensing pathways and determine whether this can be targeted to modulate outcome of infection.
Innate immune sensing of virus activates immune pathways that are distinct to those activated by mosquito biting, resulting in expression of type I interferons (IFN) and the anti-viral genes they upregulate, IFN-stimulated genes (ISG). Despite the evolution of multiple strategies by 80 arboviruses to counteract IFN they are nonetheless highly sensitive to them, suggesting that therapies designed to target these pathways could be generalisable to a range of viruses (15) (16) (17) (18) . Systemic administration of type I IFN has been used to treat HCV, although febrile-like side effects are common (19) and as such it is not suitable for e.g. long-term prophylactic use.
However, previous attempts to inhibit arbovirus infection by systemic administration of innate 85 immune agonists or type I IFN have only been efficacious when given prior to infection (20) (21) (22) (23) (24) . In contrast, we suggest targeting processes at the inoculation site, which represents a discreet identifiable locale that can be targeted post-mosquito bite, prior to the systemic dissemination of virus. However, targeting these pathways is challenging as the coordination of early innate immune responses to virus at mosquito bites are not well defined.
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In this study, we define key aspects of host response to virus at mosquito bites and demonstrate that this can be therapeutically modulated to suppress viral replication and the development of clinical disease. We suggest that for virus to successfully disseminate from the skin to blood at a sufficient level to induce a high-titre viremia, sufficiently robust levels of replication must occur at the inoculation site before an anti-viral state that follows host IFN 95 production. In the absence of treatment, successful dissemination of virus from the skin was associated with sub-optimal activation of local IFN responses. Using an immune-competent mouse model of arbovirus infection and ex vivo infection of human skin explants, we demonstrate that therapeutic manipulation of skin IFN pathways by post-exposure topical application of a widely-used generic innate immune agonist, protected against infection with 100 multiple genetically-distinct arboviruses. In doing so, we have defined key aspects of skin innate immune response to both virus and innate immune agonists at the mosquito bite, including the identification of a population of skin-resident macrophages that are sufficient to mediate agonist-induced protection from infection. Together, this work demonstrates that early events of infection at the mosquito bite are pivotal for defining the subsequent systemic 105 course and that this site can be targeted through post-exposure therapeutic intervention.
Results

Skin innate immune responses to virus infection at the inoculation site are a key determinant of the systemic course
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Studying innate immune responses at the tissue-and system-wide level to arboviruses that are medically-important in humans, has been frequently complicated by their inability to replicate in immunocompetent mice (10) . Therefore, we chose to primarily study host innate immune responses to a prototypic model arbovirus SFV (genus Alphavirus). Unlike most human arboviral pathogens, SFV is capable of efficiently replicating, disseminating systemically within, and causing clinically-observable disease in immunocompetent mice. SFV is a close relative of CHIKV (25) that has a large number of genetically-modified clones and has been used extensively to study host response to infection. SFV replicates quickly following infection of mouse skin, with viremia peaking by 24 hours post-infection (hpi). Dissemination of SFV to brain tissue can result in encephalitis, neurological signs and death (9, 26) .
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We wanted to determine whether targeting early innate immune responses in the skin had any observable effect on the later systemic course of infection. However, it was first necessary to define the kinetics and magnitude of endogenous host ISG responses to infection with SFV6, in the absence of therapies. Following infection of the foot skin, ISG expression in response to virus infection was slow and of low-magnitude compared to induction of ISG in 125 the dLN, with ISG expression not significantly elevated until 24 hpi, with levels peaking at 48 hpi (Fig 1A-D) . In comparison, the dLN rapidly and robustly upregulated ISG, with levels peaking by 16 hpi. Thus, upregulation of anti-viral ISG in the skin could be detected only after virus had disseminated systemically.
It is not clear what relevance skin-specific innate immune responses to arbovirus have on the 130 subsequent systemic course of infection, nor whether virus replication in the skin is absolutely necessary to establish viremia. To determine whether therapeutic induction of anti-viral innate immune pathways at the inoculation site could have any effect on the systemic course of infection, we injected or topically applied a range of distinct innate immune agonists to a defined cutaneous site one hour prior to infection with SFV6 (Fig 1E-K) . The TLR7 agonist 135 imiquimod (IMQ) was administered either as a subcutaneous (s.c.) injection or applied topically as a cream (Aldara™, ALD). At 24 hpi, only topical ALD and poly(I:C)-treated mice exhibited lower viral RNA at the skin inoculation site, while all innate immune agonists 
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(A-D) Mice were infected subcutaneously (s.c.) with 250 PFU SFV6 in the upper skin of the left foot. Copy number of host (A) ifnb1, (B) cxcl10 (C) ifng (D) cxcl9 and 18S RNA in skin and draining popliteal lymph node (dLN) was determined by qPCR (n=6). (E-G) 1h prior to infection with SFV6, mice were treated with either topical IMQ (Aldara, ALD) or injected s.c. with 6μg of either; aqueous IMQ, poly(dA:dT) or poly(I:C). Copy number of SFV
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RNA and host 18S was determined by qPCR at 24 hpi. Non-draining LN was the popliteal LN contralateral to infection. (G) Virus titers in the serum were quantified by plaque assay (n=6). (H-K) Mice were left resting or pre-treated for 1h with; (H) 2mg topical ALD (n=12); (I) s.c. 6μg Poly (dA:dT) (n=12); (J) s.c. 6μg IMQ (n=10); (K) s.c. 6μg Poly (IC) (n=10); and then infected with SFV6 viruses. PID=post infection day.
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Bars significantly different to 0 h or SFV alone respectively, *p<0.05, **p<0.01, ***p<0.001, ns=not significant (Kruskal-Wallis and logrank (Mantel Cox) test) copies ifng / 10 6 18S **** **** **** Copies SFV RNA /10 7 copies 18S ** ** ** * decreased virus in the dLN (Fig 1E) . Poly(I:C) was particularly potent at decreasing viral RNA in most tissues analyzed, although viremia ( Fig 1G) and survival to infection (Fig 1K) was not 155 significantly affected. In comparison, only ALD significantly; decreased viral replication at both local tissues (skin and dLN); tissues remote from the inoculation site (non-dLN, spleen and brain); reduced infectious virus in blood; and limited the development of clinical disease ( Fig   1H) . As SFV6 is highly virulent in mice, it does not model all arboviral disease seen in humans that are often non-fatal. Therefore, to better model the human situation we also tested the 160 ability of IMQ to suppress infection with SFV4, a less virulent strain than SFV6 (Fig S1A) . Again, topical application of ALD at the site of SFV4 inoculation significantly suppressed infection.
Post exposure targeting of the inoculation site by topical application of an innate immune agonist protects mice from infection with virus
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Future treatment modalities that target early stages of infection are likely to involve postexposure treatment, e.g. once the erythema of a bite is apparent. Because pre-bite application of ALD was most efficacious in increasing host resistance to infection, we next determined its efficacy when applied post-infection. In addition, as arbovirus infection of skin always occurs in the context of an arthropod bite, we used a mouse model that additionally
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incorporates biting Aedes aegypti mosquitoes. Host response to mosquito bites include edema and an influx of leukocytes that enhances host susceptibility to infection with virus (9, 10, 27 ). In this model, application of ALD from 1 hpi onwards was highly efficacious in lowering SFV6 RNA in all tissues analysed and infectious virus levels in the blood by 24 hpi (Fig 2A,B) .
For mice in which infection was allowed to progress, topical ALD application resulted in a significant delay to the onset of neurological signs (Fig 2C) . Consistent with this, analyses of 195 brain tissue at post infection day 7 revealed extensive expression of SFV6-encoded mCherry throughout the brain in untreated mice, compared to treated mice (Fig 2D) . Similarly, topical ALD at 1hpi post infection with the less virulent SFV4 strain, significantly reduced virus levels by 24 hpi in tissues, the blood and substantially decreased mortality, with the majority of mice surviving infection (Fig 2E-G) . Importantly, protection by ALD was time-limited, as while
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treatment that was delayed until 5 hpi significantly lowered viral RNA levels, treatment delayed until 10 hpi did not significantly modulate the level of viral replication or dissemination by 24 hpi (Fig 2H) . Together these data identify the inoculation site as a key site for viral replication during the first 24 hpi and suggests that, in untreated mice, skin IFN responses are not sufficiently robust to prevent systemic dissemination. Therapeutic targeting
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of this site with topically applied innate immune agonists was therefore highly effective at suppressing both the local and subsequent systemic course of infection, significantly improving survival.
ALD induces upregulation of cutaneous ISG via canonical type I IFN receptor signalling
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Having identified the inoculation site as amenable to therapeutic targeting with topical ALD, we next wanted to determine its mode of action, as a detailed mechanistic understanding will inform the development of more targeted strategies. Importantly, ALD contains a mixture of the TLR7 agonist IMQ (5%) and isostearic acid (25%), both of which can be inflammatory in a type I IFN-independent manner (28, 29) , suggesting that IFN may be dispensable for some of 215 the beneficial effects of ALD described here. However, we found that by 24 hours post application at a mosquito bite, ALD caused widespread induction of ISG expression, with the prototypic ISGs cxcl10, ifit1, isg15 and rsad2 most highly expressed in the skin, most of which have been identified as key responders to alphavirus infection (17, 30) . Increased expression of cxcl10 could be detected by 16 hours and this increased significantly by 24 hours (Fig. S2E ).
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Interestingly however, despite a clear upregulation of ISG, we could not detect any increase in type I (ifna4, ifnb1, ifne, ifnk, ifnz) or II (ifng1) IFN transcripts in whole skin biopsies, as measured by Taqman assays or custom SYBR green qPCR assays ( (G) Mice were treated with topical ALD and levels of ifnb1 determined by qPCR at 24 h (n=6) *p<0.05, **p<0.01, ****p<0.0001, ns=not significant (Mann-Whitney and Kruskal-Wallis test)).
Skin resident cells detect topically-applied IMQ and are sufficient for mediating protection to virus
We next wanted to identify the cellular basis by which virus is detected and an anti-viral state induced and modulated by ALD at mosquito bites. Although a variety of cultured skin cells are known to express RNA-virus pattern recognition receptors, the cellular coordination of 265 innate immune responses to arbovirus at the mosquito bite are not described (10, 33) . We RNA, virus-encoded luciferase and a complete block in the release of new virus into the supernatant, for both explants derived from resting-and mosquito bitten-skin (Fig 4B-D) .
Thus, the ability of ALD to reduce viral replication occured irrespective of leukocyte 280 recruitment triggered by infection or by mosquito bite. Furthermore, the magnitude of fold decrease in viral RNA was similar in ex vivo explants to that observed in vivo (Fig. 4E ). In addition, ALD application was efficacious in limiting SFV replication when applied to nonbitten skin ( Fig. 1E-H ). Together this suggests that skin-resident cells were sufficient for mediating ALD-induced protection from virus and that skin-infiltrating leukocytes were not 285 required.
We therefore wanted to define which skin-resident cells were necessary for activating ISG expression in response to ALD. Skin-resident leukocytes include populations of gd-T cells and ROR-gT innate lymphocytes that are necessary for some inflammatory responses to repeated ALD application (35) . However, we found that NOD SCID Gamma (NSG) mice, which lack all 290 functional lymphocytes and innate lymphoid cells, were similarly protected from infection at 24hpi by ALD ( to a sub-population of dermal macrophages) (36) . To determine if BM-derived skin resident myelomonocytic cells are required to mediate ALD-protection, we infected skin explants from ccr2-null and WT mice and treated them with topical ALD. ALD was similarly efficacious 300 irrespective of ccr2 status, suggesting that the vast majority of skin-resident dermal DC and monocytic-derived cells are not required (Fig. 4G) . Indeed, IFN and ISG induction in response to ALD application was similar in ccr2-null skin as compared to WT skin (Fig. 4H,I ), suggesting that ALD-responding cells were skin-resident cells not derived from myeloid BM-precursors. (Fig. S3A,B) . These isolated 345 populations were then interrogated for their expression of ifna4, ifnb1, isg15 and rsad2 because they have been previously implicated as key for host responses to alphaviruses (30, 37, 38) and also the prototypic ISG cxcl10.
The cellular coordination of innate immune responses to virus at the tissue-wide level in mosquito-bitten skin are poorly defined. Therefore, we firstly analysed responses of skin cells
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to virus infection alone in the absence of ALD (Fig 5A) . At 24hpi, sorted stromal cells and macrophages were the only cells that expressed high levels of virus structural gene transcript E1, indicative of active replication, while DCs expressed only very low levels of viral RNA (Fig.   S3C ). This, along with our previous studies (9) , suggest that stromal cells and macrophages are key targets for viral replication of SFV at mosquito bites in vivo. Importantly, the only cell
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type expressing type I IFN in response to virus were DCs, which was limited to ifnb1 only, as no ifna4 was detected. Thus, DCs were the primary initiators of anti-viral ISG responses at virus-infected mosquito bites. However, dermal DC were present at low numbers in the skin at 24hpi, suggesting their total contribution to the tissue-wide IFN response was minimal (Fig.   S3B ). This agrees with our whole tissue analysis that demonstrated little IFN expression before 360 24 hpi (Fig. 1A) . Thus, although stromal cells and macrophages exhibited high levels of viral RNA they did not make detectable type I IFN. Nonetheless they expressed some ISG including rsad2, cxcl10 and isg15 by 24hpi (Fig. 5A ), presumably in response to DC-expressed IFN cues. All other leukocytes included in the bulk sort did not express IFN or upregulate ISG in response to virus.
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Next, to determine which cells were activated by ALD, mosquito-bitten mouse skin was treated with ALD alone (Fig. 5B, Fig. S3E ). Crucially, in contrast to virus infection, ALD induced ifnb1 expression in both the more populous skin-resident macrophages and dermal DC, while stromal cells and all other leukocytes lacked type I IFN transcripts. There was also a trend for higher ifna4 in macrophages, although this was too variable to be statistically significant in our 370 experiments. In response, stromal cells upregulated rsad2 and isg15 to high levels. As viruses have evolved mechanisms to antagonise IFN signaling we next wanted to determine if 
375
Mosquito-bitten mouse skin was digested to release cells and then FACS-sorted at 4 o C into "stroma", "macrophage", dendritic cell "DC's" and "other leukocyte" compartments as a bulk sort. All steps were undertaken in presence of transcriptional inhibitors. Copy number of gene transcripts were determined by qPCR for; ifna4, ifnb1, isg15, cxcl10, rsad2 and 18S RNA was (n=4). Cells were sourced from mosquito bitten skin that was either; (A) infected with SFV6 infection was ISG and cell type-specific. Activation of higher IFN expression in macrophages was important for two reasons; firstly, macrophages were significantly more numerous in the skin than dermal DC at 24 hpi (Fig. S3B ) and secondly, they constituted an important source of virus replication in the first 24 hours of infection ( Fig S3C and (9) ). ALD-elicited IFN appeard to be functional, as type I IFN negative stromal cells exhibited a significant decrease in viral
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RNA with ALD treatment by 24hpi, as did virus-infected macrophages (Fig. S3C ).
Together, this shows that ALD upregulated type I IFN in skin-resident macrophages that, in addition to responses of the less frequent dermal DCs, acted to induce ISG expression and thereby reduce viral replication in the skin. Furthermore, because dermal DC-deficient ccr2-null skin (36) was not compromised in its ability to express ISG or reduce virus titres in response 400 to ALD (Fig. 4H,I ), we suggest that skin-resident macrophages alone are sufficient to mediate protection. Thus, responses by skin-resident macrophages to ALD are likely sufficient to confer protection against virus infection.
Stromal cells integrate cues from IMQ-treated leukocytes to resist infection with virus
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We next wanted to determine whether signals from IMQ-activated macrophages and DCs are alone sufficient to confer protection on stromal cells from virus infection and whether this required cell-to-cell contact. The majority of dermal stromal cells are either fibroblasts or keratinocytes, both of which can be experimentally-infected with a range of arboviruses (10, 39, 40) , including SFV4 (Fig. 6A-D) . Some cultured fibroblasts have been described to express 410 a variety of receptors that sense virus, including the IMQ receptor TLR7 (41) . However, we found that FACS-isolated stromal cells ex vivo lacked detectable TLR7 (Fig. S3D) . In addition, our cultured primary dermal fibroblasts (Fig. 6B) and keratinocytes ( 
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were stimulated with IMQ for 24 hours and their supernatant given to fibroblasts at 1 hpi with luciferase-expressing SFV6-Gluc (Fig. 6D) . While supernatant from resting leukocytes had no effect on fibroblast susceptibility to infection, tissue culture supernatant from DC or macrophages treated with IMQ protected fibroblasts from infection, as measured by virusencoded luciferase.
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As infected myeloid cells and DC are susceptible to arbovirus-encoded anti-IFN mechanisms 
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Virus-encoded Gluc was assayed at 24 hpi (n=6). DC were separated from stromal cells by a cell-impermeable membrane. All cells were infected with SFV4(Xho)-EGFP and treated at 1 hpi with either 0.2 µg/ml IMQ or saline control ( Fig. 6E-H) . DC cultures themselves became infected with SFV, exhibiting high level expression of viral RNA (Fig 6G) . Nonetheless, DC were able to resist infection upon addition (1hpi) of IMQ and consequently expressed higher levels of the ISG cxcl10. Importantly, while 460 the addition of IMQ alone, or DC alone, had no effect on the ability of co-cultured stromal cells to resist infection, the combined presence of both IMQ and DC did protect keratinocytes (Fig. 6E,F and Fig S4) and fibroblasts (Fig. 6H ). This was evident by a significant decrease in viral RNA expression (Fig 6E,H) and by microscopic inspection of the stromal cell monolayer that otherwise became decimated by 24hpi, with the remaining intact cells also positive for 465 virus-encoded eGFP (Fig. 6F, Fig. S4 ). Protection from virus in stromal cells occurred in conjunction with the induction of stromal ISG expression (Fig. 6I) . While keratinocytes did not express ISG or type I IFN in response to either virus alone, IMQ alone, or both; they did significantly increase ISG expression with the addition of DC to the transwell insert. Thus, IMQinduced stromal cell protection from virus occurs in conjunction with the induction of ISG 470 expression that was licenced by extracellular cues derived from IMQ-responsive leukocytes.
ALD protects mice and human skin from infection with a variety of genetically-distinct medically-important viral pathogens
We finally wanted to determine whether activating IFN pathways by ALD at the skin 475 inoculation site could have potential applicability to a variety of genetically-distinct arboviruses of medical importance. Arboviruses are derived from several evolutionary-and genetically-divergent groups including; Togaviridae, Flaviviridae and Bunyavirales. We therefore analysed the ability of ALD to modulate the outcome of infection to a relevant representative of each of these distinct groups in mice and human skin explants. The
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prototypic Bunyamwera virus (BUNV, genus Orthobunyavirus, family Peribunyaviridae, order Bunyavirales), which like SFV is also transmitted by Aedes mosquitoes, has well-described potent IFN antagonism (4) and therefore may be resistant to ALD treatment. However, when mosquito-bitten BUNV-infected inoculation site was treated with topical ALD at 1hpi, there was a significant decrease in viral RNA in target tissues and blood (Fig. 7A-C) . Similarly, we 485 determined if topical ALD could prevent dissemination of CHIKV (a medically important pathogen of the Togaviridae family that has caused widespread outbreaks of disease) to mouse joints that were remote from the inoculation site ( Fig. 7D-G ). Mice treated with ALD 1 hpi exhibited significantly lower levels of CHIKV RNA (qPCR) and infectious virus in the ankle joint contralateral to infection, and also a decrease in CHIKV RNA in the wrists of the forelimbs.
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Finally, to determine if ALD could also reduce viral replication in human skin, we cultured explants of freshly biopsied human skin, infected them with virus and treated with topical ALD to the epidermis at 1 hpi (Fig. 7H,I ). Application of ALD resulted in a significant decrease in viral replication for both CHIKV and ZIKV (genus Flavivirus of the family Flaviviridae), as measured by viral RNA and also infectious virus for ZIKV. Together these studies demonstrate
495
that an innate immune agonist that primarily targets inoculation-site skin-resident macrophages, has a significant post-exposure prophylactic effect on the replication and dissemination of a variety of genetically-distinct medically-important viruses. (A-C) Mosquito bitten skin of mice (n=6) were infected with BUNV and treated with topical ALD from 1 hpi. At 24 hpi, copy number of BUNV RNA was determined by qPCR in skin (A) and dLN (B); and infectious virus in blood determined by plaque assay (C).
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(D-G) Mice were infected with 10 6 PFU of CHIKV (s.c.) and treated with topical ALD from 1hpi
onwards. Dissemination of virus to distal joints were assessed at 24hpi in the right ankle joint. In this study, we identified the key skin cell types in mice that coordinate anti-viral immune responses to virus and those that respond to topical ALD. We found that skin type I IFN expression to virus was restricted to the relatively infrequent DC population. In contrast, macrophages and stromal cells could not elicit IFN expression, despite a high level of viral
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RNA in these cells. Thus, skin-resident DC are key activators of the type I IFN response at the inoculation site to virus. Such specificity may reflect either; cell-type specific susceptibility to virus-encoded mechanisms to antagonise IFN activation; or the particular cell-tropism of our model arbovirus, SFV.
We suggest that the observed efficacy of our exemplar immune-modulator, ALD, was 540 explained by activation of dermal macrophages. These cells were not only otherwise deficient in their IFN expression in response to virus alone, but also can replicate high levels of virus (9) .
Therapies that specifically target dermal macrophages may provide yet enhanced efficacy.
ALD was no longer efficacious where treatment was delayed for 10 hours in our mouse model.
We suggest that this timing most likely reflects specific aspects of our model system that 545 supports rapid dissemination of SFV, itself a mouse-adapted strain. It is not clear how these kinetics apply to human infection by mosquito, although it is widely-accepted that virus may take considerably longer (several days) to disseminate from human skin to the blood (44) . This in turn may mean that the window available for post-exposure intervention in humans is conveniently longer than that observed in our model, although virus-, host-and environment- We maintained application of ALD for only five hours to a single site, suggesting systemic side effects are less likely than with prolonged exposure. However, effective post-exposure prophylaxis might entail treatment of multiple, discrete, suspected arbovirus-infected mosquito bites, even with e.g. vector repellent strategies employed. Thus, it will be important 565 to refine any future formulations such as to render the application of treatment practical.
However, it should be noted that e.g. ALD has been widely used for many years for a variety of dermatological conditions, including in primary care, and is generally well-tolerated by patients, even when repeatedly applied at the same site for several weeks (45) . Additionally, our approach would likely entail topical immunomodulation over a smaller surface area than 570 those typically treated with ALD for its licenced indications. Finally, it is noteworthy that outbreaks of arbovirus infection are explosive in nature and can be highly seasonal, enabling possible use of any prophylactic strategies to be more intensively promoted when risk of infection is known to be high. Furthermore, it is possible that those patients deemed at higher risk of complications following arbovirus infection, such as immunosuppressed individuals, or 575 e.g. those that are more susceptible to severe dengue, may particularly benefit from this strategy.
Materials and Methods
Study design
580
This controlled laboratory study was initiated to determine whether anti-viral innate immune response to arbovirus at the mosquito bite can be therapeutically-manipulated to suppress the subsequent systemic course and improve outcome of infection in mice. We investigated mammalian host responses to representative viruses from three genetically-divergent groups of arboviruses. Two of the viruses (ZIKV and CHIKV) are medically important emerging 585 arboviruses, while the others (SFV and BUNV) are model viruses that replicate efficiently in immune competent mice. As previously described (9), Ae. aegypti bite sites were infected with mosquito cell culture-derived virus in a sub-µl volume by hyperfine needle. Anesthetized mice were injected with either 6μg poly(I:C), poly(dA:dT) and IMQ (Invivogen) into skin as a 4µl aqueous volume using Hamilton syringes, at the same site as virus infection (using upper skin of left foot (9)). Poly (I:C) and poly (dA:dT) were purchased pre-complexed
615
with transfection reagent Lyovec (as the receptors for these agonists are cytoplasmic and widely expressed). 2mg Aldara (5% w/w IMQ; 25% w/w isostearic acid) was applied topically to the site of virus inoculation. Because Aldara (ALD) is a cream that can become removed by cage bedding, it was re-applied once at 6 hpi to maintain dosing. Although it is difficult to define the exact dose of IMQ provided using topical application of cream, previous studies
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have shown that dosing results in limited systemic absorption, with IMQ concentration peaking at 0.4 ng/ml blood in humans (32) , with most being retained in the absorbent stratum corneum (the outer dead keratinized layer) or otherwise removed by external processes.
Cell culture, viruses and mice.
BHK-21 cells and C6/36 mosquito cells were grown and SFV4 , SFV6 and BUNV prepared, as 625 previously described (9) . Mouse leukocytes were derived from BM-precursors; using 10ng/ml M-CSF for 6 days (macrophages); 20ng/ml GM-CSF for 6 days or 200 ng/ml Flt3L for 10 days (dendritic cells). C57Bl/6-deived primary keratinocytes (Cell biologics, USA) were grown in complete epithelia cell media as per manufacturer's instructions. Skin fibroblasts were derived from adult C57Bl/6 dermis, digested with collagenases, dispase and DNAse to release cells
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and grown for 12 days in complete DMEM.
The pCMV-SFV4 and pCMV-SFV6 backbone for production of SFV has been previously described (26, 46 specified, all mice were 6-8-week-old wild type mice (C57bl/6J). All mice were derived from a locally bred-colony maintained in a pathogen-free facility, in filter-topped cages and maintained in accordance with local and governmental regulations. Ccr2-deficient mice were 645 originally obtained from the Jackson Laboratory (stock number 004999).
Mosquito biting and virus infection
To ensure mosquitoes bit a defined area of skin (upper side of the left foot), anesthetized mice were placed onto a mosquito cage containing Ae. aegypti mosquitoes (9) . Bitten skin was injected with virus in a 1 μl volume into the skin using either; 250 PFU SFV6, 1x10^4 PFU SFV4, 650 or 2.5x10^4 PFU BUNV. For survival curves, mice were monitored closely and culled when they reached clinically defined end-points of disease. For CHIKV infection of mice, 3-4 week-old mice were infected by s.c. injection of 10 6 PFU of CHIKV in the hind-left foot pad. For skin explant studies, tissue was dissected to remove sub-dermal tissues, to leave dermis exposed, and immediately infected with by placing lower dermis into virus-containing solution for one 655 hour. Explants were then washed in saline and cultured in complete DMEM media at 37 o C/5%
CO2. ALD was applied topically to the epidermis at 1 hpi. For human explants, informed consent was obtained from the volunteer donors, and skin sourced from areas that were relatively protected from environmental insult and had no obvious lesions (upper inner arm).
Human studies were performed following ethical approval and in accordance to all applicable 660 regulations. All further details of reporter viruses, cells, primers and mice used can be obtained from the authors.
Gene expression analysis and flow cytometry Viral RNA and hosts gene transcripts were quantified by qRT-PCR and infectious virus by endpoint titration, as described previously (48) . qPCR primers for SFV and CHIKV amplified a 665 section of E1 and primers for BUNV targeted segment M (9), while primers for ZIKV amplified a section of the env gene. For SFV, CHIKV and ZIKV, qPCR assayed measured the sum value of both genome and sub-genomic RNA. For FACS, skin tissue samples were enzymatically digested with collagenase, dispase and DNAse, stained with antibodies and a viability dye (9).
Cells were analysed on a CytoFLEX (Beckman Coulter Life Sciences). For cell sorting, samples
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were kept on ice with transcriptional inhibitors and sorted using an Influx cell sorter (BD).
Immunohistochemistry and histology
Tissues were fixed in 4% methanol-free paraformaldehyde (Thermo Scientific) then dehydrated in an increasing concentration of sucrose. Fig. S1 . Pre-exposure of skin to topical ALD increased host resistance to infection with SFV4. 
